Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

ATJMED. 2024; 4(4): 118-24


The efficacy of intravitreal ranibizumab injections for treating choroidal neovascularization in wet age-related macular degeneration

Dincer Dinc, Nurhan Dincer, Kadir Eltutar.




Abstract

Aim: To evaluate the efficacy and safety of intravitreal ranibizumab injections for treating choroidal neovascularization associated with wet age-related macular degeneration.
Materials and Methods: This study included 105 eyes of 105 patients who received intravitreal ranibizumab injections for age-related macular degeneration between January 2009 and August 2010, and again between December 2019 and April 2022. Before treatment, color fundus photography, fundus fluorescein angiography, and optical coherence tomography were conducted for assessment. The first three injections were administered at one-month intervals. Additional injections were given if there was a decrease in visual acuity, active leakage observed in fundus fluorescein angiography, an increase in central retinal thickness of more than 100 μm, or the presence of subretinal fluid.
Results: The mean age of the patients was 68.3±6.11 years (range, 60–82 years). The average follow-up period was 14.2±1.3 months (range, 12–18 months). Patients received an average of 4.31±0.44 intravitreal ranibizumab injections (range, 3–6 injections). The mean preoperative best-corrected visual acuity (BCVA) was 0.1 LogMAR, which improved to 0.78 LogMAR postoperatively. BCVA increased (by 1–3 LogMAR) in 45 cases (42.85%), decreased (by 1–3 LogMAR) in 16 cases (15.23%), and remained unchanged in 44 cases (41.9%) at the 12-month follow-up. No cases of endophthalmitis or drug-induced systemic side effects were observed.
Conclusion: Intravitreal ranibizumab injection is a safe and effective treatment for choroidal neovascularization associated with wet age-related macular degeneration.

Key words: Age-related macular degeneration, choroidal neovascularization, ranibizumab






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.